CARBOPLATIN, BEVACIZUMAB, FILGRASTIM, PACLITAXEL, Ubamatamab, Ubamatamab clinical trials

REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy.

This study looks at a new combination of medicines, including one called Ubamatamab, for women with ovarian cancer that hasn't responded well to initial treatments. Researchers want to find a safe dose and see how well it shrinks cancer, hoping to offer a new option for these patients.